NovAccel
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NovAccel - overview
Established
2024
Location
Tsuchiura, Ibaraki, Japan
Primary Industry
Pharmaceuticals
About
Based in Japan and founded in 2024, NovAccel. inc, d. b. a.
NovAccel focuses on producing medical radioisotopes, particularly Actinium-225, to support the advancement of targeted alpha therapy, a cutting-edge approach in oncology. In May 2026, NovAccel raised JPY 1. 2 billion in venture funding from University of Tokyo Edge Capital Partners, Fast Track Initiative, Daiwa Corporate Investment, ATOX, and Yoshida Inc. NovAccel’s core product initiative is the development of a compact superconducting accelerator.
This proprietary technology enables the domestic production of Actinium-225, a rare and powerful isotope used in targeted alpha therapy. The company also offers joint and contract research services, leveraging its accelerator expertise to provide tailored R&D solutions to partners in the healthcare sector. Revenue is expected to be generated through the sale of radioisotopes, R&D collaborations, and contracted development services. The company plans to use its proceeds from May 2026 funding to strengthen global procurement and accelerate capital investment toward completing its medical radioisotope production facilities.
Current Investors
University of Tokyo Edge Capital Partners, Daiwa Corporate Investment, Fast Track Initiative
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development, Medicinal Chemicals & Botanicals, Molecular Chemicals
Website
https://novaccel.jp
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.